Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CPU-YL01
- Development stage
- Phase 1
- Lead developer
- China Pharmaceutical University
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
CPU-YL01 is a therapeutic vaccine candidate being developed by Jiangsu Chuangyuan Life Science and Technology in collaboration with China Pharmaceutical University for the treatment of chronic hepatitis B (CHB). As a recombinant protein-based immunotherapy, CPU-YL01 is designed to stimulate a targeted immune response against the hepatitis B virus (HBV), aiming to overcome the immune tolerance and exhaustion that characterize chronic infection. The drug is currently in Phase I clinical development (e.g., CTR20262223), where it is being evaluated for safety, tolerability, pharmacokinetics, and pharmacodynamics in adults with CHB who are receiving stable nucleos(t)ide analogue therapy. It is administered via intramuscular injection.
Beyond the preview
Go deeper on CPU-YL01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CPU-YL01.